Primary AML tumor samples were selected based on having known HLA haplotypes for HLA-A, B, C and HLA-DR, and at least one or more common recurrent mutations in either NPM1, FLT3, DNMT3A, IDH1, IDH2, KIT, or RAS from previous clinical evaluation. Here, DNMT3A is linked to acute myeloid leukemia.